Olanzapine; Samidorphan L-malate Patent Expiration
Olanzapine; Samidorphan L-Malate is used for treating bipolar disorder and schizophrenia with reduced weight gain and adverse metabolic effects by combining olanzapine and samidorphan. It was first introduced by Alkermes Inc
Olanzapine; Samidorphan L-malate Patents
Given below is the list of patents protecting Olanzapine; Samidorphan L-malate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Lybalvi | US11707466 | Immediate release multilayer tablet | Nov 12, 2041 | Alkermes Inc |
| Lybalvi | US11951111 | Immediate release multilayer tablet | Nov 12, 2041 | Alkermes Inc |
| Lybalvi | US8778960 | Methods for treating antipsychotic-induced weight gain | Feb 13, 2032 | Alkermes Inc |
| Lybalvi | US9119848 | Morphinan derivatives for the treatment of drug overdose | Aug 30, 2031 | Alkermes Inc |
| Lybalvi | US10300054 | Methods for treating antipsychotic-induced weight gain | Aug 23, 2031 | Alkermes Inc |
| Lybalvi | US10716785 | Methods for treating antipsychotic-induced weight gain | Aug 23, 2031 | Alkermes Inc |
| Lybalvi | US11185541 | Methods for treating antipsychotic-induced weight gain | Aug 23, 2031 | Alkermes Inc |
| Lybalvi | US11241425 | Composition for treating mental illness | Aug 23, 2031 | Alkermes Inc |
| Lybalvi | US11351166 | Methods for treating antipsychotic-induced weight gain | Aug 23, 2031 | Alkermes Inc |
| Lybalvi | US11793805 | Methods for treating antipsychotic-induced weight gain | Aug 23, 2031 | Alkermes Inc |
| Lybalvi | US9126977 | Methods for treating antipsychotic-induced weight gain | Aug 23, 2031 | Alkermes Inc |
| Lybalvi | US9517235 | Methods for treating antipsychotic-induced weight gain | Aug 23, 2031 | Alkermes Inc |
| Lybalvi | US7262298 | 4-hydroxybenzomorphans | Nov 23, 2025 | Alkermes Inc |
| Lybalvi | US7956187 | Method for decreasing opioid metabolism |
Oct 31, 2021
(Expired) | Alkermes Inc |
| Lybalvi | US8252929 | 8-carboxamido-2,6-methano-3-benzazocines |
Oct 31, 2021
(Expired) | Alkermes Inc |
Olanzapine; Samidorphan L-malate's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List